Navigation Links
Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
Date:1/23/2013

http://Non-24.com.

About TasimelteonTasimelteon is a circadian regulator in development for the treatment of Non-24.  Tasimelteon is a melatonin agonist of the human MT1 and MT2 receptors, with greater specificity for MT2.  Tasimelteon's ability to reset the master body clock in the suprachiasmatic nucleus (SCN), located in the hypothalamus, results in the entrainment of the body's melatonin and cortisol rhythms to align to the 24-hour day-night cycle.  Tasimelteon is currently in Phase III development for Non-24 and Phase IIb/III for Major Depressive Disorder (MDD).

Conference Call
Vanda has scheduled a conference call for today, Wednesday, January 23, 2013 at 9 AM ET to discuss the trial results.  Investors can call 1-866-713-8565 (domestic) and 1-617-597-5324 (international) and use passcode 60037962.  A replay of the call will be available beginning Wednesday, January 23, 2013, at 11:00 AM ET and will be accessible until Wednesday, January 30, 2013, at 11:59 PM ET.  The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers.  The access number is 97367748.

The conference call will be broadcast simultaneously on Vanda's website, http://www.vandapharma.com.  Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download and install any necessary software.  The call will also be archived on Vanda's website for a period of 30 days, through February 21, 2013.

About Vanda Pharmaceuticals Inc.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit http://
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
2. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
3. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
4. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
5. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
6. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
7. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
8. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
9. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
10. Vanda Pharmaceuticals Reports First Quarter 2012 Results
11. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Breckenridge Pharmaceutical, Inc. announced ... with MSN Laboratories Pvt. Ltd. ( Hyderabad, India ... commercialize several new ANDAs.  Under the terms of the ... exclusively to Breckenridge for the U.S. market, and Breckenridge ... Breckenridge and MSN have agreed to develop an oral ...
(Date:12/19/2014)...  Monarch America Inc. (OTCQB: CANK) ("Monarch America" or ... provide this review of the Company,s recent achievements and ... "Over this past year, we achieved many of our ... to say that Monarch America is in a stronger ... been," stated Eric Hagen , CEO of Monarch ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/942kh3/micro_market ... "Micro Market Monitor: North American Dermatology Diagnostic Devices ... http://photos.prnewswire.com/prnh/20130307/600769 Cosmetic ... has resulted in fueling the overall demand of ... of these dermatology devices is to assist in ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3
... Columbia, Jan. 7, 2011 Enox Biopharma, Inc. CEO, John ... Emerging Company Finance Conference on Wednesday, January 12 at 8:10 ... Francis Drake Hotel in San Francisco. Dr. ... ability to embed nitric oxide into polymer based medical devices ...
... ANGELES, Jan. 7, 2011 MD+DI ( ... ( Medical Product Manufacturing News ), and OrthoTec, ... today announced session topics for the upcoming virtual event, ... 26, 2011, from 11am until 5pm Eastern time. ...
Cached Medicine Technology:Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference. 2Virtual Event Dedicated to Cutting-Edge Trends in Implantable Medical Devices Offers Sessions on Orthopedic and Cardio Applications 2Virtual Event Dedicated to Cutting-Edge Trends in Implantable Medical Devices Offers Sessions on Orthopedic and Cardio Applications 3
(Date:12/19/2014)... (HealthDay News) -- All children should have their eyesight ... every year, eye experts say. The new vision-screening ... of the U.S. National Center for Children,s Vision Health. ... group require screening for eye problems, particularly vision ... ("lazy eye") and strabismus (a disorder of eye alignment). ...
(Date:12/19/2014)... News) -- Dense bunches of bacteria called biofilms can be ... finds. The researchers said these biofilms were especially ... presence of these biofilms may represent an increased likelihood of ... a person,s risk for the disease, the researchers said. ... may coat the mucus layer of cells lining the colon, ...
(Date:12/19/2014)... Surviving Mesothelioma says thousands of water pipes in the ... can leach asbestos into drinking water as they age. ... the Surviving Mesothelioma website. , According to the EPA, ... water mains made of asbestos cement are the major source ... consumers from mesothelioma , water providers are subject to routine ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Park Medical Center in Estes Park, Colo. The top ... Smith has recently placed more than 900 healthcare executives ... is a 25-bed, not-for-profit critical access hospital and level ...
(Date:12/19/2014)... Cranbury, NJ (PRWEB) December 19, 2014 ... of Inside Patient Care: Pharmacy & Clinics™, an ... entire healthcare team treating and caring for patients ... As primary care expands to provide optimal access ... Clinics™ offers a forum for the team treating ...
Breaking Medicine News(10 mins):Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Could Bacteria Play a Role in Colon Cancer? 2Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3
... study has found that brains of people who are victims ... The study, available in the current issue of Brain, ... de Montréal, the Montreal Neurological Institute and the Newcastle University ... to last a lifetime which impedes normal functioning people to ...
... 523 children and adolescents in the United States had ... a major national study called SEARCH for Diabetes in ... diabetes among youth under the age of 20 ever ... Ph.D., M.S., associate professor of epidemiology and prevention at ...
... sign of faster “biological ageing,” suggests research published ahead // ... ,The authors base their findings on a study of almost ... were female twins. ,X-rays of both hands were ... and a blood sample was taken to assess “biological ageing” ...
... A little-known antibiotic shows early promise as an anti-cancer ... most human tumors, // according to researchers at the ... ,Their findings appear in the Oct. 1 issue of ... gene believed to be over-expressed in cancer cells to ...
... better than non-contrast enhanced sonography, according to a ... Davis School of Medicine department of radiology in ... liver, spleen or renal injuries. Contrast-enhanced sonography depicted ... sonography revealed 11 (50%). ,“The main focus ...
... after years of dictatorship and war, Iraqi craniofacial and ... treating many of the most serious injuries caused by ... forward was last year's "Kuwait Plast 2005" meeting, in ... counterparts in a 5-day exchange of surgical knowledge and ...
Cached Medicine News:Health News:Understanding Reasons for Tone deafness 2Health News:One in 523 Children and Adolescents Have Diabetes 2Health News:One in 523 Children and Adolescents Have Diabetes 3Health News:Osteoarthritis May be Sign of Faster “Biological Ageing 2Health News:Antibiotic Inhibits Cancer Gene Activity 2Health News:Journal of Craniofacial Surgery Publishes Research by Iraqi Surgeons 2
... cream powder Moisture: 10% Ash: ... 700 gm/cm 2 Gel pH (1.5%): 5.0 ... (1.5%): 80 95C A (430 nm, 1.5%): ... >= 25,000 Ohms EEO (-m r ...
... easy and economical generation of a hypoxic ... Chamber utilizes a surface-type seal where all ... by a stainless steel ring clamp for ... and semi-spherical top and bottom provide minimum ...
... range of miniTHERM incubators is available, ensuring ... solution for their specific requirements. miniTHERM incubators ... compact and extremely space saving. Their size ... It is possible to stack up to ...
In microbiological laboratories and for in vitro fertilization, as well as in cancer research or tissue engineering, the Heraeus CO2 incubator BBD 6220 provides the best contamination protection and ...
Medicine Products: